Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.
about
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.Tumor regression is mediated via the induction of HER263-71- specific CD8+ CTL activity in a 4T1.2/HER2 tumor model: no involvement of CD80 in tumor control.Future Roles of Lapatinib in ErbB2-Positive Breast Cancer: Adjuvant and Neoadjuvant Trials.Targeting HER2 in breast cancer: overview of long-term experiencePathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy.Pre-operative systemic therapy in locally advanced breast cancer: a single institution experience.Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.Potential use of humanized antibodies in the treatment of breast cancer.Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials.Use of trastuzumab for the treatment of early stage breast cancer.Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients.Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma.Breast cancer: beyond the cutting edge.A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).HER2 assessment by silver in situ hybridization: where are we now?Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa.Trastuzumab cardiotoxicity: from clinical trials to experimental studies.Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II studTrastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel.Monitoring circulating epithelial tumor cells (CETCs) during primary systemic chemotherapy including trastuzumab for early prediction of outcome in patients with Her2/neu-positive tumors.A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers.Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice.
P2860
Q33680890-EF9C53B4-36DD-4209-B9DE-F0D4D83CE57EQ33688821-9A86DCE8-2F5C-433F-94B3-B636388E58DCQ34096246-FC83432F-D26B-45E8-8833-BB52019DAE41Q34272044-874E7B7B-93C0-4EEE-8130-7FA730A30F01Q34344198-A60C61E3-435E-405C-97CD-0D33AB949F87Q34855870-36D4809F-C77B-451A-8B83-D3852A21CA14Q35562526-F49B43D0-C819-4B26-BC1F-FEDA04F531C4Q35572926-C3D3C882-8BC1-49AD-ABE7-18574778C873Q35742760-51920B81-E32B-4725-A610-B0D00B0483CAQ36532110-DF14C1D0-6D23-454A-9BB7-4666515B48DFQ36569759-204F7085-B11D-4980-8F85-6DDFD5B4B15FQ36573813-D151FC36-F743-4A9C-92B8-F40997966869Q36613598-CCBBD40E-2641-4280-A77C-5DDEFA0E2A1FQ36766067-7EECB098-0DCE-4974-ACDC-BED7FFF1886CQ36871664-762639C2-2929-4786-B999-E1CA0B0695F5Q37209672-DE23C4E5-7C07-4A7A-AFFD-F63C23D3FF1EQ37401557-6D5FCC56-4AFE-46AD-B89D-E2DA2CF16FD7Q37598890-83EBED4E-C9D0-413A-A4C4-257FB134161EQ38029563-E8FECF96-9994-4297-84D2-4F709D3B9BCFQ38314355-34C4A351-10EB-49AF-B154-EE4734C4523DQ38884705-0C4AB7D4-1DFF-4CA7-AB53-4B12E304084FQ38974785-BA390D3D-F9EF-49C5-A353-87AEAAE7811AQ39221924-C66366FB-88FA-4FE5-AA9D-949574E9B0A0Q39612713-E44B7B04-B9EB-463B-9B70-E3184BC0E401Q39841379-88D4612A-5072-4993-9178-DD91BB6A7525Q42536856-E32ECFAC-FA21-4F64-8205-7FA7EA3EAB82Q42637089-8A36F859-4B94-44D9-A98B-5184E36083B6Q43466172-D5E619F4-6FAE-48C5-BDD5-37B2F33E4CA7Q53398198-A4A6402F-6250-4FAA-8473-BC5B9698142BQ54338904-514D2EB0-F2EE-4044-AE1B-FA05536C3DFA
P2860
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Pre-operative systemic (neo-ad ...... a multicenter phase II trial.
@en
Pre-operative systemic
@nl
type
label
Pre-operative systemic (neo-ad ...... a multicenter phase II trial.
@en
Pre-operative systemic
@nl
prefLabel
Pre-operative systemic (neo-ad ...... a multicenter phase II trial.
@en
Pre-operative systemic
@nl
P2093
P356
P1433
P1476
Pre-operative systemic (neo-ad ...... a multicenter phase II trial.
@en
P2093
B P Coudert
D Mery-Mignard
J-L Misset
L Vanlemmens
P304
P356
10.1093/ANNONC/MDJ096
P577
2005-12-06T00:00:00Z